Mural Oncology plc (MURA) Stock Analysis & Investment Frameworks
Mural Oncology plc (MURA) stock analysis on Invetso. Review Mural Oncology plc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Mural Oncology plc Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: IE
Mural Oncology plc Key Financial Metrics
- Market Cap: $35.38M
- Revenue: $N/A
- ROE: -90.71%
- ROIC: -60.14%
- Dividend Yield: N/A
About Mural Oncology plc
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.